Evidence map›Paper›PMID 35871146›Full record

ArticleResearch in social & administrative pharmacy : RSAP2022

Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemic.

Janson Jacob, Daniel Aintabi, Melissa DeJonckheere, Shirley A Cohen-Mekelburg, John I Allen, David N Irani, A Mark Fendrick, Akbar K Waljee, Peter D R Higgins, Jeffrey A Berinstein

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research in social & administrative pharmacy : RSAP, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Janson JacobDepartment of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA.
Daniel AintabiDepartment of Medicine, St. Joseph Mercy Ann Arbor Hospital, Ypsilanti, MI, USA.
Melissa DeJonckheereDepartment of Family Medicine, University of Michigan, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.
Shirley A Cohen-MekelburgDepartment of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, USA; Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, USA.
John I AllenDepartment of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, USA.
David N IraniDepartment of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.
A Mark FendrickDepartment of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; Center for Value-Based Insurance Design, University of Michigan, Ann Arbor, MI, USA.
Akbar K WaljeeDepartment of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, USA; Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, USA.
Peter D R HigginsDepartment of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA; Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, USA.
Jeffrey A BerinsteinDepartment of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, USA. Electronic address: jberinst@med.umich.edu.
University of Michigan · USMichigan Medicine · USVA Ann Arbor Healthcare System · USTrinity Health Ann Arbor Hospital · US

Funding

Training Program in Gastrointestinal EpidemiologyT32DK062708 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Peter D.R. Higgins, Elliot Tapper · 2003 to 2026
$3.9M
NIDDK NIH HHS T32 DK062708
6 · The paper itself

Abstract

backgroundIn response to the COVID-19 pandemic, the CDC issued guidance advising patients and providers to adopt social distancing practices such as home-based infusions (H-BI).

methodsWe performed a mixed methods evaluation to summarize perceptions, concerns, and experiences with H-BI among all inflammatory bowel disease patients 18-90 years of age who transitioned to home-based infliximab or vedolizumab infusions between March to July 2020 at a tertiary care center. Semi-structured interviews were conducted and analyzed using an iterative, inductive thematic approach. Baseline characteristics and outcome on safety, COVID-19 transmission, delays in infusions, and H-BI persistence were collected.

resultsOf the 57 participants who transitioned to H-BI, 20 (33%) responded. Four major categories and six major themes related to expectations, experience, perceived safety, and logistical factors were identified. Initial perceptions were mixed, however these resolved. One patient developed COVID-19, one patient experienced an adverse event, 12 (21%) patients experienced an infusion delay, and 6 (11%) patients transitioned from H-BI. DISCUSSION: Despite mixed initial perceptions, respondents had a positive experience with most respondents planning to continue H-BI after the pandemic resolves. Several real-world actionable barriers were identified related to scheduling, communication between stakeholders, and nursing quality. No major safety concerns were identified.

Indexed as

COVID-19Inflammatory Bowel DiseasesChronic DiseaseHumansInfliximabPandemicsInfliximabBiologicsCOVID-19Inflammatory bowel diseaseInfusions

Identifiers

PMID35871146
PMCPMC9238022
OpenAlexW4283703652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.